« Return to News | Awards & Advancement

Blueprint Medicines secures $40 Million in Series A for cancer treatment

Monday, April 11, 2011 01:16 PM

Blueprint Medicines, a company focused on the molecular blueprint of cancer to develop cancer therapies, will close a $40 million Series A financing led by Third Rock Ventures. Proceeds from the financing will be used to develop new cancer therapies--using the company's proprietary compound library and Insights-to-Validation Platform that target the driver molecular aberrations of cancer and emerging resistance mechanisms to certain cancer patients.

"Over the past decade, targeted kinase inhibitors have been successfully designed, advanced into clinical trials and delivered to patients, forever changing the way cancer is treated," said Dr. Nicholas Lydon, a co-founder of Blueprint. "We are now at a crossroads where innovative drug discovery and development could again enable a transformative shift in cancer treatment. By leveraging the growing body of molecular and cancer genome data and focusing on patients with clearly defined molecular aberrations, Blueprint Medicines is positioned to develop the selective cancer treatments that will make this transformation possible."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.